242 related articles for article (PubMed ID: 38599220)
41. Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial.
Tomaniak M; Chichareon P; Klimczak-Tomaniak D; Takahashi K; Kogame N; Modolo R; Wang R; Ono M; Hara H; Gao C; Kawashima H; Rademaker-Havinga T; Garg S; Curzen N; Haude M; Kochman J; Gori T; Montalescot G; Angiolillo DJ; Capodanno D; Storey RF; Hamm C; Vranckx P; Valgimigli M; Windecker S; Onuma Y; Serruys PW; Anderson R
Clin Res Cardiol; 2020 Jul; 109(7):930-943. PubMed ID: 31925529
[TBL] [Abstract][Full Text] [Related]
42. Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials.
Li J; Wang Q; Wu C; Qu X; Zhang L; He X; Ma S; Qiu M; Wang X
Cardiology; 2023; 148(4):363-373. PubMed ID: 37094558
[TBL] [Abstract][Full Text] [Related]
43. Comparison of 3- to 6-Month Versus 12-Month Dual Antiplatelet Therapy After Coronary Intervention Using the Contemporary Drug-Eluting Stents With Ultrathin Struts: The HOST-IDEA Randomized Clinical Trial.
Han JK; Hwang D; Yang S; Park SH; Kang J; Yang HM; Park KW; Kang HJ; Koo BK; Hur SH; Kim W; Kim SY; Park SH; Han SH; Kim SH; Shin S; Kim YH; Park K; Lee N; Lee SJ; Kim JW; Kim HS
Circulation; 2023 May; 147(18):1358-1368. PubMed ID: 36871230
[TBL] [Abstract][Full Text] [Related]
44. Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting.
Franzone A; McFadden E; Leonardi S; Piccolo R; Vranckx P; Serruys PW; Benit E; Liebetrau C; Janssens L; Ferrario M; Zurakowski A; Diletti R; Dominici M; Huber K; Slagboom T; Buszman P; Bolognese L; Tumscitz C; Bryniarski K; Aminian A; Vrolix M; Petrov I; Garg S; Naber C; Prokopczuk J; Hamm C; Steg PG; Heg D; Jüni P; Windecker S; Valgimigli M;
J Am Coll Cardiol; 2019 Nov; 74(18):2223-2234. PubMed ID: 31672177
[TBL] [Abstract][Full Text] [Related]
45. Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials.
Giacoppo D; Matsuda Y; Fovino LN; D'Amico G; Gargiulo G; Byrne RA; Capodanno D; Valgimigli M; Mehran R; Tarantini G
Eur Heart J; 2021 Jan; 42(4):308-319. PubMed ID: 33284979
[TBL] [Abstract][Full Text] [Related]
46. The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y
O'Donoghue ML; Murphy SA; Sabatine MS
Circulation; 2020 Aug; 142(6):538-545. PubMed ID: 32551860
[TBL] [Abstract][Full Text] [Related]
47. Long-term Effects of P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention: 3-Year Follow-up of the SMART-CHOICE Randomized Clinical Trial.
Choi KH; Park YH; Song YB; Park TK; Lee JM; Yang JH; Choi JH; Choi SH; Oh JH; Chun WJ; Jang WJ; Im ES; Jeong JO; Cho BR; Oh SK; Yun KH; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Gwon HC; Hahn JY;
JAMA Cardiol; 2022 Nov; 7(11):1100-1108. PubMed ID: 36169938
[TBL] [Abstract][Full Text] [Related]
48. An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial.
Natsuaki M; Watanabe H; Morimoto T; Yamamoto K; Obayashi Y; Nishikawa R; Ando K; Domei T; Suwa S; Ogita M; Isawa T; Takenaka H; Yamamoto T; Ishikawa T; Hisauchi I; Wakabayashi K; Onishi Y; Hibi K; Kawai K; Yoshida R; Suzuki H; Nakazawa G; Kusuyama T; Morishima I; Ono K; Kimura T
Circulation; 2024 Feb; 149(8):585-600. PubMed ID: 37994553
[TBL] [Abstract][Full Text] [Related]
49. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.
Gimbel M; Qaderdan K; Willemsen L; Hermanides R; Bergmeijer T; de Vrey E; Heestermans T; Tjon Joe Gin M; Waalewijn R; Hofma S; den Hartog F; Jukema W; von Birgelen C; Voskuil M; Kelder J; Deneer V; Ten Berg J
Lancet; 2020 Apr; 395(10233):1374-1381. PubMed ID: 32334703
[TBL] [Abstract][Full Text] [Related]
50. Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis.
Khan SU; Singh M; Valavoor S; Khan MU; Lone AN; Khan MZ; Khan MS; Mani P; Kapadia SR; Michos ED; Stone GW; Kalra A; Bhatt DL
Circulation; 2020 Oct; 142(15):1425-1436. PubMed ID: 32795096
[TBL] [Abstract][Full Text] [Related]
51. A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction.
Rao SV; Kirsch B; Bhatt DL; Budaj A; Coppolecchia R; Eikelboom J; James SK; Jones WS; Merkely B; Keller L; Hermanides RS; Campo G; Ferreiro JL; Shibasaki T; Mundl H; Alexander JH;
Circulation; 2022 Oct; 146(16):1196-1206. PubMed ID: 36030390
[TBL] [Abstract][Full Text] [Related]
52. Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review.
Kamran H; Jneid H; Kayani WT; Virani SS; Levine GN; Nambi V; Khalid U
JAMA; 2021 Apr; 325(15):1545-1555. PubMed ID: 33877270
[TBL] [Abstract][Full Text] [Related]
53. Utility of a pharmacogenetic-driven algorithm in guiding dual antiplatelet therapy for patients undergoing coronary drug-eluting stent implantation in China.
Lyu SQ; Zhu J; Wang J; Wu S; Zhang H; Shao XH; Yang YM
Eur J Clin Pharmacol; 2022 Feb; 78(2):215-225. PubMed ID: 34636928
[TBL] [Abstract][Full Text] [Related]
54. Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR.
Escaned J; Cao D; Baber U; Nicolas J; Sartori S; Zhang Z; Dangas G; Angiolillo DJ; Briguori C; Cohen DJ; Collier T; Dudek D; Gibson M; Gil R; Huber K; Kaul U; Kornowski R; Krucoff MW; Kunadian V; Mehta S; Moliterno DJ; Ohman EM; Oldroyd KG; Sardella G; Sharma SK; Shlofmitz R; Weisz G; Witzenbichler B; Pocock S; Mehran R
Eur Heart J; 2021 Dec; 42(45):4624-4634. PubMed ID: 34662382
[TBL] [Abstract][Full Text] [Related]
55. Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy after percutaneous coronary intervention in patients with acute coronary syndromes (SMART-DATE) prospective multicenter randomized trial.
Lee JM; Cho DK; Hahn JY; Song YB; Park TK; Oh JH; Lee JB; Doh JH; Kim SH; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC
Am Heart J; 2016 Dec; 182():1-8. PubMed ID: 27914488
[TBL] [Abstract][Full Text] [Related]
56. Pooled Analysis of Bleeding, Major Adverse Cardiovascular Events, and All-Cause Mortality in Clinical Trials of Time-Constrained Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention.
McClure JD; Ramsay JC; Berry C
J Am Heart Assoc; 2020 Aug; 9(16):e017109. PubMed ID: 32779497
[TBL] [Abstract][Full Text] [Related]
57. One-month DAPT with ticagrelor and aspirin for patients undergoing coronary artery bypass grafting: rationale and design of the randomised, multicentre, double-blind, placebo-controlled ODIN trial.
Sandner S; Gaudino M; Redfors B; Angiolillo DJ; Ben-Yehuda O; Bhatt DL; Fremes SE; Lamy A; Marano R; Mehran R; Pocock S; Rao SV; Spertus JA; Weinsaft JW; Wells G; Ruel M
EuroIntervention; 2024 Mar; 20(5):e322-e328. PubMed ID: 38436365
[TBL] [Abstract][Full Text] [Related]
58. Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial.
Costa F; Vranckx P; Leonardi S; Moscarella E; Ando G; Calabro P; Oreto G; Zijlstra F; Valgimigli M
Eur Heart J; 2015 May; 36(20):1242-51. PubMed ID: 25718355
[TBL] [Abstract][Full Text] [Related]
59. Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events.
Hara H; van Klaveren D; Takahashi K; Kogame N; Chichareon P; Modolo R; Tomaniak M; Ono M; Kawashima H; Wang R; Gao C; Niethammer M; Fontos G; Angioi M; Ribeiro VG; Barbato E; Leandro S; Hamm C; Valgimigli M; Windecker S; Jüni P; Steg PG; Verbeeck J; Tijssen JGP; Sharif F; Onuma Y; Serruys PW;
Circ Cardiovasc Qual Outcomes; 2020 Aug; 13(8):e006660. PubMed ID: 32762446
[TBL] [Abstract][Full Text] [Related]
60. Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis.
Valgimigli M; Smits PC; Frigoli E; Bongiovanni D; Tijssen J; Hovasse T; Mafragi A; Ruifrok WT; Karageorgiev D; Aminian A; Garducci S; Merkely B; Routledge H; Ando K; Diaz Fernandez JF; Cuisset T; Nesa Malik FT; Halabi M; Belle L; Din J; Beygui F; Abhyankar A; Reczuch K; Pedrazzini G; Heg D; Vranckx P;
Eur Heart J; 2022 Sep; 43(33):3100-3114. PubMed ID: 35580836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
